Batavia Biosciences, a contract development and manufacturing organization, has partnered with ChromaTan, Inc. for the development and integration of BioRMB (formerly known as Continuous Countercurrent Tangential Chromatography or CCTC) technology into Batavia’s AAV HIP-Vax manufacturing platform. The project aims to improve AAV manufacturing and reduce manufacturing costs through process intensification.
 
Recombinant adeno-associated virus (rAAV) vectors are spearheading the development of next generation treatments for debilitating and life-threatening disorders. However, demand for rAAV is exceeding production capacity.
 
Continuous chromatography has been shown to greatly contribute to the intensification of manufacturing processes for monoclonal antibodies. Batavia Biosciences expects to increase its rAAV production capacity and to further reduce the associated cost of goods through integration of ChromaTan’s BioRMB – a novel column-free real moving bed continuous chromatography platform – into Batavia’s proprietary HIP-Vax manufacturing platform.
 
“The promise of next generation platforms both upstream and downstream in the field of gene therapy is very powerful for multiple reasons such as improvements in manufacturability, process economics, improved recovery and product quality. This exciting partnership enabled by NIIMBL, will empower us to take that idea a step further – by directly integrating these hyper efficient next generation platforms we have the potential to transform rAAV manufacturing as we know it,” said Oleg Shinkazh, Chief Technical officer at Chromatan.
 
Peter Abbink, Managing Director at Batavia Biosciences, Inc., said, “At Batavia, we continuously seek innovative solutions to fuel our mission to enhance the accessibility and availability of critical life-changing treatments. We are privileged to have the backing of NIIMBL and are thrilled to embark on a productive partnership with ChromaTan on this endeavor.”
 
This project was developed with an award from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance from the U.S. Department of Commerce, National Institute of Standards and Technology.